Two main factors behind Sanofi's dialog with Danish authorities

Of the six companies participating in the market consultation on vaccine production in Denmark, only Sanofi has an mRNA vaccine in development, which is what the Danish PM has called for. The French pharmaceutical giant does not agree to an interview, but relates that it has had a dialog with Danish authorities for two reasons.

Sanofi General Manager / Operational Head Vaccines Denmark, Norway & Iceland Per H. Aabakken | Photo: Sanofi/PR

French life science giant Sanofi is one of three global companies interested in producing vaccines in Denmark as part of a tender organized by the Danish government and the Danish State Serum Institute (SSI).

Three Danish firms have also expressed interest, although Sanofi is the only one working on an mRNA vaccine, which Danish Prime Minister Mette Frederiksen has expressed a preference for.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Rumored GN purchase unlikely but not impossible, say analysts

A low value assessment, a high structural value, and no dominant shareholders make GN Group a reasonable investment case for international private equity firms and industrial players. But just how likely is it? Analysts reveal their best bets for what a GN acquisition could look like.

New CFO wants to shake things up at WSA

A mere month into her new job, Marianne Wiinholt, WS Audiology’s fifth chief financial officer since the firm was established through a merger in 2019, is heralding great structural changes.

Further reading

Related articles

Latest news

See all jobs